PL373910A1 - Nowe podstawione pochodne sulfamianowe jako środki przeciwdrgawkowe - Google Patents

Nowe podstawione pochodne sulfamianowe jako środki przeciwdrgawkowe

Info

Publication number: PL373910A1
Authority: PL; Poland
Prior art keywords: novel substituted; anticonvulsant derivatives; sulfamate anticonvulsant; substituted sulfamate; derivatives
Prior art date: 2002-05-13

Application number

PL03373910A

Other languages

English (en)

Inventor

Ahmed Abdel-Magid

Cynthia Maryanoff

Steven Mehrman

Kirk Sorgi

Frank Villani

Cheryl P. Kordik

Allen B. Reitz

Bruce Eliot Maryanoff

Original Assignee

Ortho-Mcneil Pharmaceutical, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-13

Filing date

2003-05-09

Publication date

2005-09-19

2003-05-09 Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.

2005-09-19 Publication of PL373910A1 publication Critical patent/PL373910A1/pl

Links

230000001773 anti-convulsant effect Effects 0.000 title 1
239000001961 anticonvulsive agent Substances 0.000 title 1
229960003965 antiepileptics Drugs 0.000 title 1
IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical class NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyridine Compounds (AREA)
Saccharide Compounds (AREA)

PL03373910A 2002-05-13 2003-05-09 Nowe podstawione pochodne sulfamianowe jako środki przeciwdrgawkowe PL373910A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US37801702P	2002-05-13	2002-05-13

Publications (1)

Publication Number	Publication Date
PL373910A1 true PL373910A1 (pl)	2005-09-19

Family

ID=29549890

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03373910A PL373910A1 (pl)	2002-05-13	2003-05-09	Nowe podstawione pochodne sulfamianowe jako środki przeciwdrgawkowe

Country Status (19)

Country	Link
US (2)	US7060725B2 (pl)
EP (1)	EP1506212A2 (pl)
JP (1)	JP2005526852A (pl)
CN (1)	CN1665828B (pl)
AR (1)	AR040412A1 (pl)
AU (1)	AU2003232112B2 (pl)
BR (1)	BR0309964A (pl)
CA (1)	CA2485966A1 (pl)
HR (1)	HRP20041042A2 (pl)
IL (1)	IL165108A0 (pl)
MX (1)	MXPA04011232A (pl)
NO (1)	NO20045369L (pl)
NZ (1)	NZ537139A (pl)
PL (1)	PL373910A1 (pl)
RU (1)	RU2328502C2 (pl)
TW (1)	TWI281472B (pl)
UA (1)	UA78566C2 (pl)
WO (1)	WO2003097656A2 (pl)
ZA (1)	ZA200409989B (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060088886A1 (en) *	2004-10-25	2006-04-27	Anlong Ouyang	Topiramate analogs
US7638291B2 (en) *	2004-10-25	2009-12-29	Seradyn, Inc.	Immunoassays for topiramate
WO2007099388A1 (en) *	2006-03-01	2007-09-07	Glade Organics Private Limited	An improved process for the manufacture of topiramate
US9303038B2 (en)	2011-09-06	2016-04-05	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy and neurological diseases
US9738631B2 (en)	2012-05-07	2017-08-22	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of depression
JP2015522531A (ja)	2012-05-07	2015-08-06	セリックスビオプライヴェートリミテッド	神経筋疾患及び神経変性疾患の治療のための組成物及び方法
US9309233B2 (en)	2012-05-08	2016-04-12	Cellix Bio Private Limited	Compositions and methods for the treatment of blood clotting disorders
US9266823B2 (en)	2012-05-08	2016-02-23	Cellix Bio Private Limited	Compositions and methods for the treatment of parkinson's disease
US9403826B2 (en)	2012-05-08	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en)	2012-05-08	2016-12-20	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en)	2012-05-08	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological degenerative disorders
WO2013168002A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological conditions
WO2013168015A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en)	2012-05-10	2016-01-26	Cellix Bio Private Limited	Compositions and methods for the treatment of respiratory disorders
WO2013167997A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en)	2012-05-10	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of moderate to severe pain
US9339484B2 (en)	2012-05-10	2016-05-17	Cellix Bio Private Limited	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9499527B2 (en)	2012-05-10	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of familial amyloid polyneuropathy
SG11201407318UA (en)	2012-05-10	2014-12-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of metabolic syndrome
WO2013168000A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of severe pain
WO2013168011A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of chronic pain
WO2013168004A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of fibromyalgia pain
US9315461B2 (en)	2012-05-10	2016-04-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurologic diseases
US9499526B2 (en)	2012-05-10	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of neurologic diseases
AU2013264896A1 (en)	2012-05-23	2014-11-27	Cellixbio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9498461B2 (en)	2012-05-23	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
WO2013175347A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of respiratory disorders
WO2013175344A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
AU2013264820A1 (en)	2012-05-23	2014-11-27	Cellixbio Private Limited	Compositions and methods for treatment of mucositis
WO2013175376A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of local pain
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en)	2012-08-03	2014-02-06	Mahesh Kandula	Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en)	2012-09-06	2017-04-18	Cellix Bio Private Limited	Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en)	2012-09-08	2014-03-13	Cellixbio Private Limited	Compositions and methods for the treatment of inflammation and lipid disorders
HUE038423T2 (hu)	2012-12-07	2018-10-29	Glycomimetics Inc	E-szelektin antagonistákat felhasználó vegyületek, készítmények és eljárások vérképzõ sejtek mobilizációjára
US8652527B1 (en)	2013-03-13	2014-02-18	Upsher-Smith Laboratories, Inc	Extended-release topiramate capsules
US9101545B2 (en)	2013-03-15	2015-08-11	Upsher-Smith Laboratories, Inc.	Extended-release topiramate capsules
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en)	2013-06-04	2015-12-30	Cellix Bio Private Ltd	Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
CN103910770B (zh) *	2014-03-14	2017-01-04	天津南开允公医药科技有限公司	一种托吡酯的制备方法以及该方法中所涉及的中间体晶型及其制备方法
EP3240779B1 (en)	2014-09-26	2020-10-28	Cellixbio Private Limited	Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es)	2014-09-29	2020-12-16	Cellix Bio Private Ltd	Compuestos y composiciones para el tratamiento de esclerosis múltiple
CA2965449C (en)	2014-10-27	2020-11-10	Cellix Bio Private Limited	Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
CN107207411A (zh)	2014-12-01	2017-09-26	塞尔利克斯生物私人有限公司	用于治疗多发性硬化的组合物和方法
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
ES2905771T3 (es)	2015-01-06	2022-04-12	Cellix Bio Private Ltd	Composiciones y procedimientos para el tratamiento de la inflamación y del dolor
US20210087059A1 (en) *	2018-03-27	2021-03-25	Daikin Industries, Ltd.	Production method for lithium sulfamate, and novel lithium sulfamate
CN110655542A (zh) *	2018-06-29	2020-01-07	鲁南制药集团股份有限公司	一种2,3:4,5-双-O-(1-甲基亚乙基)-β-D-吡喃果糖氯磺酸酯的晶型
CN114685526A (zh) *	2020-12-25	2022-07-01	长沙博源医疗科技有限公司	一种托吡酯衍生物、免疫原、抗托吡酯特异性抗体及其制备方法与应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4513006A (en) *	1983-09-26	1985-04-23	Mcneil Lab., Inc.	Anticonvulsant sulfamate derivatives
US5194446A (en) *	1989-06-12	1993-03-16	A. H. Robins Company, Incorporated	Compounds having one or more aminosulfaonyloxy radicals useful as pharmaceuticals
US5273993A (en) *	1989-06-12	1993-12-28	A. H. Robins Company, Incorporated	Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals
PT94305B (pt)	1989-06-12	1997-02-28	Robins Co Inc A H	Processo para a preparacao de compostos tendo um ou mais radicais aminossulfoniloxi uteis como produtos farmaceuticos
US5192785A (en) *	1989-09-03	1993-03-09	A. H. Robins Company, Incorporated	Sulfamates as antiglaucoma agents
US5025031A (en) *	1989-11-30	1991-06-18	A. H. Robins Co., Inc.	Aryl and aryloxyalkyl sulfamate esters useful as anticonvulsants
AU651244B2 (en) *	1991-09-19	1994-07-14	Mcneilab, Inc.	Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol
US5242942A (en) *	1992-04-28	1993-09-07	Mcneilab, Inc.	Anticonvulsant fructopyranose cyclic sulfites and sulfates
WO1995017406A1 (en) *	1993-12-23	1995-06-29	Ortho Pharmaceutical Corporation	Anticonvulsant pseudofructopyranose sulfamates
US5998380A (en)	1995-10-13	1999-12-07	New England Medical Center Hospitals, Inc.	Treatment of migraine
US5952187A (en)	1995-12-01	1999-09-14	Oxis International, Inc.	Topiramate immunoassay
JP3602906B2 (ja) *	1996-03-05	2004-12-15	富士写真フイルム株式会社	熱現像感光材料

2003
- 2003-05-08 US US10/434,387 patent/US7060725B2/en not_active Expired - Lifetime
- 2003-05-09 AU AU2003232112A patent/AU2003232112B2/en not_active Ceased
- 2003-05-09 MX MXPA04011232A patent/MXPA04011232A/es active IP Right Grant
- 2003-05-09 EP EP03753013A patent/EP1506212A2/en not_active Withdrawn
- 2003-05-09 CN CN038159910A patent/CN1665828B/zh not_active Expired - Fee Related
- 2003-05-09 RU RU2004133334/04A patent/RU2328502C2/ru active
- 2003-05-09 BR BR0309964-4A patent/BR0309964A/pt not_active IP Right Cessation
- 2003-05-09 NZ NZ537139A patent/NZ537139A/en unknown
- 2003-05-09 PL PL03373910A patent/PL373910A1/pl not_active Application Discontinuation
- 2003-05-09 JP JP2004505387A patent/JP2005526852A/ja active Pending
- 2003-05-09 CA CA002485966A patent/CA2485966A1/en not_active Abandoned
- 2003-05-09 WO PCT/US2003/014796 patent/WO2003097656A2/en not_active Ceased
- 2003-05-09 HR HR20041042A patent/HRP20041042A2/xx not_active Application Discontinuation
- 2003-05-13 TW TW092112867A patent/TWI281472B/zh not_active IP Right Cessation
- 2003-05-13 AR AR20030101652A patent/AR040412A1/es unknown
- 2003-09-05 UA UA20041210256A patent/UA78566C2/uk unknown
2004
- 2004-11-09 IL IL16510804A patent/IL165108A0/xx unknown
- 2004-12-08 NO NO20045369A patent/NO20045369L/no not_active Application Discontinuation
- 2004-12-09 ZA ZA200409989A patent/ZA200409989B/xx unknown
2005
- 2005-11-02 US US11/265,670 patent/US7560459B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
TWI281472B (en)	2007-05-21
RU2004133334A (ru)	2005-06-10
RU2328502C2 (ru)	2008-07-10
TW200404078A (en)	2004-03-16
MXPA04011232A (es)	2005-08-16
BR0309964A (pt)	2005-03-01
CN1665828A (zh)	2005-09-07
WO2003097656A2 (en)	2003-11-27
US7060725B2 (en)	2006-06-13
EP1506212A2 (en)	2005-02-16
JP2005526852A (ja)	2005-09-08
US20060058373A1 (en)	2006-03-16
WO2003097656A3 (en)	2004-06-10
US7560459B2 (en)	2009-07-14
HRP20041042A2 (hr)	2009-04-30
AU2003232112B2 (en)	2008-12-18
AU2003232112A1 (en)	2003-12-02
CN1665828B (zh)	2012-06-27
AR040412A1 (es)	2005-04-06
ZA200409989B (en)	2006-02-22
IL165108A0 (en)	2005-12-18
UA78566C2 (en)	2007-04-10
NO20045369L (no)	2004-12-08
US20040038911A1 (en)	2004-02-26
CA2485966A1 (en)	2003-11-27
NZ537139A (en)	2008-05-30

Legal Events

Date	Code	Title	Description
2011-07-29	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
IL165108A0 (en)	2005-12-18	Novel substituted sulfamate anticonvulsant derivatives
AP1850A (en)	2008-05-26	Spiroindolineplperidine derivatives
EG24050A (en)	2008-04-13	Heterocylocarboxamide derivatives
IL166084A0 (en)	2006-01-15	Novel benzodioxoles
PL371678A1 (pl)	2005-06-27	Nowe pochodne pirydyny i pirymidyny
PL374718A1 (pl)	2005-10-31	Azolidynono-winylowe pochodne skondensowanego benzenu
IL166121A0 (en)	2006-01-15	Indole-3-sulphur derivatives
PL373598A1 (pl)	2005-09-05	Nowe benzonaftyrydyny
EP1522540A4 (en)	2011-08-10	AZAARENE DERIVATIVES
AU2003233465A8 (en)	2003-10-13	Structural member
GB2389660B (en)	2004-11-24	NMR Imanging
PL376475A1 (pl)	2005-12-27	Pochodne N-podstawionej 2-oksodihydropirydyny
IL163652A0 (en)	2005-12-18	Substituted hydroxyethylamines
IL166426A0 (en)	2006-01-15	N-biarylmethyl aminocycloalkanecarboxamide derivatives
IL163529A0 (en)	2005-12-18	Novel spinosyn-producing polyketidesynthases
IL159698A0 (en)	2004-06-20	Novel anticonvulsant derivative salts
PT1487778E (pt)	2012-07-26	Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
AU2003222659A8 (en)	2003-11-03	23-o-substituted 5-o-mycaminosyltylonide derivatives
IL166740A0 (en)	2006-01-15	Substituted heterocyclylpyrimidines
IL169505A0 (en)	2007-07-04	Novel anticonvulsant derivatives salts
EP1531854A4 (en)	2006-06-28	O-DERIVATED NOCATHIACIN DERIVATIVES
GB0213488D0 (en)	2002-07-24	2-Naphthamide derivatives
PL377325A1 (pl)	2006-01-23	Podstawione benzodioksepiny
AU2003243397A8 (en)	2003-12-19	Homo-camptothecin derivatives
HK1071760A (en)	2005-07-29	Novel substituted sulfamate anticonvulsant derivatives